IVIXF (Invion) Margin of Safety % (DCF Earnings Based): N/A (As of Jun. 25, 2026)


IVIXF Invion Ltd IVIXF
16 GF Score
Price $0.04
GF Value $0.17
! 2 Warning Signs
View Full Analysis

What is Invion Margin of Safety % (DCF Earnings Based)?

Margin of Safety % (DCF Earnings Based) = (Intrinsic Value: DCF (Earnings Based) - Current Price) / Intrinsic Value: DCF (Earnings Based).

Note: Discounted Earnings model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Invion's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Earnings Based) is not calculated.

IVIXF vs ZTS, UTHR: Margin of Safety % (DCF Earnings Based) Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Invion's Margin of Safety % (DCF Earnings Based), along with its competitors' market caps and Margin of Safety % (DCF Earnings Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Invion Margin of Safety % (DCF Earnings Based) vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Invion's Margin of Safety % (DCF Earnings Based) distribution charts can be found below:

* The bar in red indicates where Invion's Margin of Safety % (DCF Earnings Based) falls into.


IVIXF
16GF Score
Invion Ltd IVIXF
Margin of Safety % (DCF Earnings Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Invion (IVIXF) Overvalued in 2026?

Based on GuruFocus' analysis, Invion stock appears to be undervalued. The current stock price of $0.04 is trading 78.3% below its estimated GF Value™ of $0.17.

Key valuation signals for IVIXF:

  • Margin of Safety % (DCF Earnings Based): N/A
  • GF Value™: $0.17 vs. price of $0.04 (78.3% below fair value)
  • GF Score™: 16/100 with 2 warning signs

No single metric tells the full story. See the IVIXF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Invion Business Description

Other Exchanges 7C8:GermanyIVX:Australia
Address 692 High Street, East Kew, VIC, AUS, 3102
Invion Ltd is an Australian clinical-stage pharmaceutical drug development company. It is engaged in the development of PhotoDynamic Therapy (PDT) for cancer treatments called Photosoft, for the treatment of a range of cancers, and infectious diseases. The company produces topical and intravenous products suitable for use in skin cancer and solid tumors, such as ovarian, prostate, and lung cancer. Invion has developed a portfolio of patent protected compounds. Its drug candidate is INV043, a novel photosensitiser which has the potential to work as a therapy and a diagnostic tool.
16GF Score

Get the complete analysis for IVIXF

Margin of Safety % (DCF Earnings Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.04
Price
$0.17
GF Value